Analysis reveals distinct immune escape mechanisms in HNSCC, suggesting post-translational modification impacts immunotherapy efficacy.
Post-translational modification (PTM) plays a crucial role in head and neck squamous cell carcinoma (HNSCC) progression, and their specific prognostic implications in HNSCC have not been thoroughly investigated. TCGA-HNSCC, GSE41613, GSE42743, and GSE65858 were merged into a meta-cohort, and 21 types of PTM were generated consensus cluster. Then, WGCNA was utilized to identify module genes. Finally, a machine learning approach was used to create the PTM.score. This analysis revealed 2 distinct subtypes of PTMs, each characterized by unique molecular signatures. By integrating different categories of genes, including DEGs, prognosis-related DEGs, module genes, and PTM-related genes, 13 hub genes were identified, and a PTM.score was developed. PTM.score was rigorously validated across 4 independent external cohorts and an in-house cohort, demonstrating its reliability and potential applicability. The PTM.score serves a dual purpose in its application, as it encapsulates the essential clinical context and offers valuable insights regarding the efficacy of immunotherapy treatments. In particular, patients categorized with a high PTM.score displayed a TME that was more actively engaged, which corresponded with a poor prognosis. Furthermore, these patients demonstrated a low level of responsiveness to immunotherapy interventions. In addition, an analysis utilizing spatial transcriptomics revealed that the PTM.score was markedly expressed within the tumor cells. This novel PTM-related prognostic signature could effectively assess the prognosis and therapeutic responses of HNSCC patients, providing new perspectives for individualized treatment for the patient population.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: